Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. ABBV
4. META
5. SPY
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
(NASDAQ: MIRM) Delayed: 111.07 +3.30 (3.06%)
Previous Close $107.77    52 Week High $ 
Open $105.48    52 Week Low $ 
Day High $111.36    P/E N/A 
Day Low $105.18    EPS $ 
Volume 1,129,074